Pharma Focus Europe

Essential Pharma Obtains European Rights to Colobreathe® (Colistimethate Sodium) Through Acquisition From Teva

Monday, January 08, 2024

Essential Pharma, an international specialty pharmaceutical group committed to providing sustainable access to low-volume, clinically established pharmaceutical products in key therapeutic areas, has successfully concluded the acquisition of European rights to Colobreathe® from Teva Laboratories UK Limited.

Colobreathe® is designed for the management of chronic pulmonary infections caused by Pseudomonas aeruginosa (PsA) in cystic fibrosis patients aged 6 years and older. The prevalence of bacterial lung infections with PsA is high in cystic fibrosis patients due to the buildup of mucus, facilitating bacterial growth and leading to infections, lung damage, and respiratory issues. The product consists of a capsule containing the active pharmaceutical ingredient and a Turbospin inhaler for drug delivery.

As part of the agreement, Essential Pharma has gained exclusive rights to Colobreathe® in European markets, where the product is currently available in over 20 countries, including the UK. This acquisition marks a significant milestone as it represents Essential Pharma's first foray into rare disease products, solidifying its position as a prominent specialty pharmaceutical business dedicated to ensuring the continuous supply of crucial medicines with high clinical significance for patients, healthcare providers, and caregivers.

Emma Johnson, CEO of Essential Pharma, stated, “Our primary focus is on securing sustainable access to essential medications for patients. Colobreathe® is a vital treatment for a common complication in cystic fibrosis patients. By acquiring the European rights to this medicine, which will be our inaugural product indicated for a rare disease, we aim to ensure ongoing access for cystic fibrosis patients in Europe.”

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva